CN115428945B - 一种包含氢镁素的缓释抗氧化组合物及其应用 - Google Patents
一种包含氢镁素的缓释抗氧化组合物及其应用 Download PDFInfo
- Publication number
- CN115428945B CN115428945B CN202211104598.XA CN202211104598A CN115428945B CN 115428945 B CN115428945 B CN 115428945B CN 202211104598 A CN202211104598 A CN 202211104598A CN 115428945 B CN115428945 B CN 115428945B
- Authority
- CN
- China
- Prior art keywords
- magnesium
- hydrogen
- parts
- composition
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 229910012375 magnesium hydride Inorganic materials 0.000 title claims abstract description 24
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 14
- 238000013268 sustained release Methods 0.000 title description 2
- 239000012730 sustained-release form Substances 0.000 title description 2
- 239000011777 magnesium Substances 0.000 claims abstract description 66
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 66
- 239000003094 microcapsule Substances 0.000 claims abstract description 42
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 40
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 40
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 39
- 239000011162 core material Substances 0.000 claims abstract description 33
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 30
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 25
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 25
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000002131 composite material Substances 0.000 claims abstract description 25
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 25
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 25
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001630 malic acid Substances 0.000 claims abstract description 25
- 235000011090 malic acid Nutrition 0.000 claims abstract description 25
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 25
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000001694 spray drying Methods 0.000 claims abstract description 18
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 15
- 229910052786 argon Inorganic materials 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 239000007789 gas Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims description 80
- 229910052739 hydrogen Inorganic materials 0.000 claims description 80
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 62
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 46
- 150000002431 hydrogen Chemical class 0.000 claims description 31
- 239000000377 silicon dioxide Substances 0.000 claims description 31
- 238000003756 stirring Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 19
- 239000000661 sodium alginate Substances 0.000 claims description 19
- 235000010413 sodium alginate Nutrition 0.000 claims description 19
- 229940005550 sodium alginate Drugs 0.000 claims description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims description 18
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 18
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 18
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 18
- 229920001249 ethyl cellulose Polymers 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 14
- 229960004667 ethyl cellulose Drugs 0.000 claims description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 12
- 229910052710 silicon Inorganic materials 0.000 claims description 12
- 239000010703 silicon Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 229910052684 Cerium Inorganic materials 0.000 claims description 8
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- GHLITDDQOMIBFS-UHFFFAOYSA-H cerium(3+);tricarbonate Chemical compound [Ce+3].[Ce+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GHLITDDQOMIBFS-UHFFFAOYSA-H 0.000 claims description 6
- YNFYQHZKLWMOPA-UHFFFAOYSA-H cerium(3+);tricarbonate;hexahydrate Chemical compound O.O.O.O.O.O.[Ce+3].[Ce+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O YNFYQHZKLWMOPA-UHFFFAOYSA-H 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000005245 sintering Methods 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000006041 probiotic Substances 0.000 claims description 5
- 235000018291 probiotics Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 abstract description 12
- 230000009471 action Effects 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 206010051246 Photodermatosis Diseases 0.000 abstract description 2
- 238000003915 air pollution Methods 0.000 abstract description 2
- 238000002309 gasification Methods 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000008845 photoaging Effects 0.000 abstract description 2
- 230000008809 cell oxidative stress Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 239000000047 product Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000032683 aging Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 239000011258 core-shell material Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- JFQQIWNDAXACSR-UHFFFAOYSA-L magnesium malate Chemical compound [Mg+2].[O-]C(=O)C(O)CC([O-])=O JFQQIWNDAXACSR-UHFFFAOYSA-L 0.000 description 5
- 229940096424 magnesium malate Drugs 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000011232 storage material Substances 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- -1 hydrogen ions Chemical class 0.000 description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036559 skin health Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229910003087 TiOx Inorganic materials 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HLLICFJUWSZHRJ-UHFFFAOYSA-N tioxidazole Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)SC2=C1 HLLICFJUWSZHRJ-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
本申请涉及一种包含氢镁素的缓释抗氧化组合物及其应用,以重量份计,组合物包括以下组分:氢镁素微胶囊80‑160份、γ‑氨基丁酸180‑220份、烟酰胺1‑4份,氢镁素微胶囊为氢镁素和苹果酸混合芯材与透明质酸钠复合壁材通过喷雾干燥法制备得到;芯材与壁材的质量百分比比例为1:(2‑3.5);混合芯材中氢镁素和苹果酸的质量百分比比例为(3‑5):(10‑20);氢镁素以氧化镁为原料,在高温下通过与氢氩混合气体的气化反应制备得到。本发明的组合物通过氢镁素微胶囊的特殊结构结合镁基微马达的推动作用,实现了人为而有效地控制氢镁素的靶向缓释控释功能,可有效减弱由空气污染及光老化引起的细胞氧化应激和炎症,为皮肤提供有效的保护措施,实现皮肤的抗氧化作用。
Description
技术领域
本发明属于储氢镁基化合物材料领域,尤其涉及一种包含氢镁素的缓释抗氧化组合物及其应用。
背景技术
空气污染、光老化主要通过氧化应激机制加速皮肤老化,这是皮肤健康的主要威胁。“衰老的真正原因”就是随着身体内细胞的减少ATP产生降低,而减少的细胞无法还原,由于与NAD共同作用产生ATP的是负氢离子,在线粒体的内膜中,在酶的作用下一旦负氢离子与辅酶NAD+(烟酰胺腺嘌呤二核苷酸)紧密连接,就会生成NADH。NADH为辅酶,它恢复到NAD+时释放并传递电子,最终在ATP合成酶的作用下由ADP(二磷酸腺苷)与无机磷酸(Pi)制造出三磷酸腺苷(ATP),为人体补充能量,减缓人体衰老。负氢离子具有很强的还原性,负氢离子不仅用于还原有毒自由基,还能与NAD共同生成ATP,可用于食品化妆品里,细胞可以吸收这种具有纳米颗粒形式的物质。因此,氢气作为唯一可以进入线粒体并清除有氧自由基的分子,H2在体内可以发挥作用,预防疾病和恢复健康,缓解衰老。
专利CN105456288A公开了一种补镁兼具抗氧化作用的保健药品制剂及其制备方法,所述保健药品制剂包括主要有效成分镁剂和辅料,所述镁剂为MgH2微纳米粉,所述辅料为常用药物制剂辅料。与现有的补镁制剂相比,该发明所述制剂具有一次服用同时补充人体必需微量元素镁及中和氧自由基的具有抗氧化作用的氢元素,储存及服用方便,转化效率高,吸收效果好、成本低、无毒副作用的优点。长期服用该制剂,可有效预防因身体缺镁而引起的各种不良症状,同时引入氢的抗氧化作用,对消炎、强身健体、延缓衰老、预防疾病也有益处。该发明虽然利用氢和镁元素实现人体的抗氧化作用,但是氢和镁的利用率较低,且无法实现靶向缓释控释的功能。
因此,为了提高氢和镁的利用率,在镁基储氢材料外包裹一层核壳结构成为了最新的研究方向。专利CN105642883A公开了一种核壳结构镁基储氢材料,于核壳结构镁基储氢材料成分中,镁颗粒质量百分比为60-85%,壳层钛氧化物质量百分比为15-40%,在壳层钛氧化物TiOx中,x=0.5-1.8;所述镁颗粒为纳米或微米颗粒,壳层钛氧化物的厚度为60-200nm。该发明的制备方法是采用溶胶-凝胶法制备钛氧化物壳层,该壳层钛氧化物能有效提高镁的吸放氢性能,并且核壳结构材料在空气中稳定、抗氧化;该发明具有核壳结构的镁基材料应用于固态储氢,能够有效提高吸放氢的速率,降低吸放氢过程所需的温度。该发明镁基储氢材料制备方法操作相对简单,合成温度低,条件易于控制,并且能够实现镁基储氢材料壳层的均匀包覆。但是,该发明的氢无法用于护肤品领域,且该发明的核壳结构无法实现氢的缓释控释。
因此,如何获取一种能够应用于护肤品抗氧化,并且实现氢的靶向缓释控释,提高氢镁素利用率,成为本领域一个亟待解决的重要技术问题。
发明内容
针对上述现有技术中存在的缺陷,本发明的目的在于提供一种生产成本低利用率高的具有抗氧化功能的组合物,该组合物具有靶向缓释控释的氢镁素微胶囊,借助镁基微马达的推动作用,实现烟酰胺、γ-氨基丁酸、透明质酸钠A的深层渗透,达到协同的独特作用。
具体的,本发明提供一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素微胶囊 80-160份
γ-氨基丁酸 180-220份
烟酰胺 1-4份
氢镁素微胶囊为,以氢镁素和苹果酸为混合芯材,海藻酸钠、乙基纤维素和透明质酸钠为复合壁材通过喷雾干燥法制备得到;
芯材与壁材的质量百分比比例为1:(2-3.5);混合芯材中氢镁素和苹果酸的质量百分比比例为(3-5):(10-20);
氢镁素以氧化镁为原料,在高温下通过与氢氩混合气体的气化反应制备得到。
本发明制备的固态储氢镁化合物氢镁素是一种经过特有的工艺将氢气储存镁化合物的一系列物理化学氢化过程,制备得到的氢镁素是微纳米尺寸级别,是一种氢镁素微纳米马达,利用释放氢气的气体推动作用,协助药物定向运输、局部治疗,本发明的氢镁素微纳米马达作为一种内源性驱动马达,能够智能响应微环境而自主到达靶部位,实现目标部位局部精准给药,增强疗效。同时,本发明的氢镁素的缓释控释放氢功能亦有双重保障,其一,氢镁素合成后表面被氧化物覆盖,状态稳定,遇水缓慢释放氢气,其表面的氧化物在人体内在苹果酸的作用下逐步分解,其内的氢镁素逐步释放氢气,其二,本发明使用氢镁素微胶囊结构,一方面可以实现氢气的靶向缓释控释,最大限度地发挥芯材的效能;另一方面,使用微胶囊技术将重要成分包裹起来,保护氢镁素以及本发明的镁基微马达结构和功能,减少外界环境对氢镁素和苹果酸的影响和破坏,延长了产品的功效保持期。
本发明组合物中的氢镁素,在人体无论哪个部位反应最终产物都只生成水,不会有任何其他毒副残留物的产生,反而具有补水性,同时又具有补镁的功效。人体内的水分大部分要进入细胞内进行工作,但是以大分子或大分子团存在的水,很难通过细胞膜进入细胞内部。组合物中氢镁素中的负氢离子是进入人体细胞后发生反应的,反应后生成的水直接存在干细胞内部,帮助细胞进行工作,其细胞内补水的功效是其他同类产品不可能达到的,从而达到防止衰老的目的。同时作为负氢离子载体共同作用于人体,清除有毒自由基、促进体内代谢,激活机体自身抗氧化物,改善衰老。
该组合物通过氢镁素微纳米马达效应控释氢气,推动马达运动的特性,实现烟酰胺、γ-氨基丁酸、透明质酸钠的深层渗透,达到协同的独特作用,具有防止皮肤老化,维持皮肤弹性等保护皮肤,其作用机理能间接促进胶原蛋白和透明质酸的形成,从而起到保护皮肤健康的作用。同时,组合物中苹果酸作为控释剂,生成的苹果酸镁支持能量产生,加快新陈代谢;烟酰胺加速肌肤内黑色素细胞的脱落,促进肌肤新陈代谢,具有抗心律失常,抗炎等功效;γ-氨基丁酸有防止皮肤干燥老化,促生长因子等功效;氢镁素微胶囊壁材中的透明质酸钠保持肌肤水分,增加皮肤弹性。
进一步的,组合物还包括益生菌,本发明的益生菌为复方嗜酸乳杆菌、枯草杆菌、双歧杆菌、地衣芽孢杆菌中的至少一种。
进一步的,氢镁素微胶囊的制备方法包括以下步骤:
S1:将氢镁素和苹果酸混合均匀,得到混合芯材;
S2:称取海藻酸钠、乙基纤维素和透明质酸钠加入水中,加热溶解,搅拌均匀得到壁材溶液;
S3:将混合芯材加入壁材溶液中,充分混合后高压均质,采用喷雾干燥法制备得到氢镁素微胶囊。
本发明氢镁素微胶囊的芯材选择氢镁素和苹果酸共混联用,氢镁素表层覆盖一层氧化物,进入人体内在苹果酸的作用下氧化物逐渐分解,实现氢镁素的缓释和控释,其次,氢镁素通过介孔二氧化硅的负载,能够最大程度的提高放氢率;苹果酸用于护肤品具有抗氧化和去角质的功效,对于治疗一系列皮肤问题,包括细纹和皱纹、色素沉着过度、粉刺、毛孔粗大、粟粒疹、疣、老茧等具有显著功效,同时,苹果酸是一种有效的皮肤提炼剂,可以促进皮肤细胞外层的脱落,进而具有抗衰老作用。此外,苹果酸和镁反应生成苹果酸镁具有多重功效,苹果酸镁能支持能量产生,对纤维肌具有治疗作用,也可用于治疗慢性疲劳综合征,进而加快新陈代谢。
本发明使用海藻酸钠、乙基纤维素和透明质酸钠复合壁材,海藻酸钠是从褐藻类的海带或马尾藻中提取碘和甘露醇之后的副产物。其分子由β-D-甘露糖醛酸和α-L-古洛糖醛酸通过(1→4)键连接而成,是一种天然多糖。海藻酸钠的稳定性、溶解性、黏附性和安全性较好,对微胶囊产品的整体粒径均匀性、缓释性能及稳定性有积极意义。透明质酸钠是一种非硫酸化的糖胺聚糖,作为一种可生物降解、生物相容性好、无毒、无免疫原性的天然多糖,存在羧基、羟基等多个可进行交联等化学改性的位点,可作为微胶囊的壁材包裹天然活性成分。将透明质酸钠作为壁材制备的微胶囊,既能在特定部位实现靶向作用,又能提高微胶囊的稳定性。乙基纤维素具有粘合、填充、成膜等作用,其易溶于各种有机溶剂,有良好的热稳定性等性质。因此,本发明制备的复合壁材使微胶囊性能稳定,并能实现微胶囊的靶向缓释控释。
喷雾干燥在将液体剂型转化成粉末方面起着至关重要的作用。并且,在许多情况下,有必要将生物活性药物封装到壁材中,以保护它们不受严酷的过程和环境条件的影响,并在正确的时间将药物在体内正确的时间和地点运送到体内正确的位置,而干粉形式具有更高的稳定性,更好的环境保护(如氧化,光和温度),更容易处理和储存,并在水溶液中再分散。因此,喷雾干燥是一种常用的封装药物的方法。喷雾干燥技术是利用一股加热气流将液体制剂(包括壳和芯材)转化为微胶囊干粉的一种技术,因其生产成本低,在各种包封方法中可用性好,在医药和食品行业中应用最为广泛。
进一步的,喷雾干燥法的具体参数为:进风温度为120-200℃,进样速度为1.5-4ml〃min-1,吸气功率为80-100%。
进一步的,壁材中海藻酸钠、乙基纤维素和透明质酸钠的质量百分比比例为(7-10):(2-3):(1-2)。
进一步的,氢镁素的制备方法为:超高温加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体,将氧化镁晶体与改性介孔二氧化硅加入有机溶液中搅拌均匀后离心,将离心后的固体用有机溶剂清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体,将复合粉体放入高温烧结反应炉中,通入氢氩混合气体,加热到400-800℃,反应12-15h得到氢镁素。
进一步的,改性介孔二氧化硅为经过铈改性的纳米介孔二氧化硅。具体改性方式为:
将六水合碳酸铈加入浓度为0.010-0.013g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为(0.07-0.10):1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅。
进一步的,超高温加热的温度为2000-3000℃。
进一步的,氢氩混合气体中氢气与氩气的体积百分比比例为1:(14-16)。
第二方面,提供一种包含氢镁素的缓释抗氧化组合物在抗衰老食品、药品,或抗衰老护肤品中的应用。
本发明的优点具体在于:
1)本发明提供一种生产成本低,利用率高的具有抗氧化功能的组合物,该组合物具有靶向缓释控释的氢镁素微胶囊,遇水缓慢释放氢气,同时作为负氢离子载体共同作用于人体,清除有毒自由基、促进体内代谢,激活机体自身抗氧化物,改善衰老;同时,借助镁基微马达的推动作用,实现烟酰胺、γ-氨基丁酸、透明质酸钠A的深层渗透,达到协同的独特作用。
2)本发明使用氢镁素微胶囊结构,一方面可以实现氢气的靶向缓释控释,最大限度地发挥芯材的效能;另一方面,使用微胶囊技术将重要成分包裹起来,保护芯材,减少外界环境对氢镁素和苹果酸的影响和破坏,延长了产品的功效保持期。
3)本发明组合物中苹果酸用于护肤品具有抗氧化和去角质的功效,对于治疗一系列皮肤问题,包括细纹和皱纹、色素沉着过度、粉刺、毛孔粗大、粟粒疹、疣、老茧等具有显著功效,同时,苹果酸是一种有效的皮肤提炼剂,可以促进皮肤细胞外层的脱落,进而具有抗衰老作用。苹果酸和镁反应生成苹果酸镁具有多重功效,苹果酸镁能支持能量产生,对纤维肌具有治疗作用,也可用于治疗慢性疲劳综合征,进而加快新陈代谢。烟酰胺加速肌肤内黑色素细胞的脱落,促进肌肤新陈代谢,具有抗心律失常,抗炎等功效;γ-氨基丁酸有防止皮肤干燥老化,促生长因子等功效;氢镁素微胶囊壁材中的透明质酸钠保持肌肤水分,增加皮肤弹性。
4)本发明使用介孔二氧化硅作为原料制备的氢镁素,成本低廉,工序简单,安全性高。经过铈改性的介孔二氧化硅克服了传统介孔二氧化硅孔容积小,孔道深的弊端,吸附性明显提升,能够负载更多的氢,提高了氢镁素的储氢能力。同时,本发明的介孔二氧化硅及所制备的氢镁素为微纳米级,利用其微纳米尺寸效应及包覆作用,达到局部控释氢气推动马达运动的作用,实现γ-氨基丁酸的深层渗透,达到氢镁素和γ-氨基丁酸协同改善的功效,进一步实现了组合物的靶向缓释。
附图说明
图1为本发明实施例3在第15天和第30天使用本发明组合物对美容效果有效率影响结果示意图。
具体实施方式
为了使本发明的目的、技术方案和优点更加清楚,下面将结合实施例对本发明作进一步地详细描述。
一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素微胶囊 80-160份
γ-氨基丁酸 180-220份
烟酰胺 1-4份
组合物还包括益生菌,益生菌为复方嗜酸乳杆菌、枯草杆菌、双歧杆菌、地衣芽孢杆菌中的至少一种。组合物还包括膳食纤维、抗性糊精等辅料。
氢镁素微胶囊中混合芯材与复合壁材的质量百分比比例为1:(2-3.5);混合芯材为质量百分比比例为(3-5):(10-20)的氢镁素和苹果酸;复合壁材为质量百分比比例为(7-10):(2-3):(1-2)的海藻酸钠、乙基纤维素和透明质酸钠;
氢镁素微胶囊通过喷雾干燥法制备得到,具体方法包括以下步骤:
S1、氢镁素的制备
1.1以氧化镁为原料,在2000-3000℃下加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体;
1.2制备改性介孔二氧化硅:将六水合碳酸铈加入浓度为0.010-0.013g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为(0.07-0.10):1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅;
1.3将氧化镁晶体与改性介孔二氧化硅加入N,N-二甲基甲酰胺中搅拌均匀后离心,将离心后的固体清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体;
1.4将复合粉体放入高温烧结反应炉中,通入体积百分比比例为1:(14-16)的氢氩混合气体,加热到400-800℃,反应12-15h得到氢镁素。
S2、将氢镁素和苹果酸按比例混合均匀,得到混合芯材;
S3:按比例称取海藻酸钠、乙基纤维素和透明质酸钠加入水中,加热溶解,搅拌均匀得到壁材溶液;
S3:将混合芯材加入壁材溶液中,充分混合后高压均质,采用喷雾干燥法制备得到氢镁素微胶囊,喷雾干燥法的具体参数为:进风温度为120-200℃,进样速度为1.5-4ml〃min-1,吸气功率为80-100%。
实施例1
一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素微胶囊 150份
γ-氨基丁酸 180份
烟酰胺 3份
氢镁素微胶囊中混合芯材与复合壁材的质量百分比比例为1:3;混合芯材为质量百分比比例为4:15的氢镁素和苹果酸;复合壁材为质量百分比比例为8:3:2的海藻酸钠、乙基纤维素和透明质酸钠;
氢镁素微胶囊通过喷雾干燥法制备得到,具体方法包括以下步骤:
S1、氢镁素的制备
1.1以氧化镁为原料,在2500℃下加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体;
1.2制备改性介孔二氧化硅:将六水合碳酸铈加入浓度为0.012g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为0.1:1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅;
1.3将氧化镁晶体与改性介孔二氧化硅加入N,N-二甲基甲酰胺中搅拌均匀后离心,将离心后的固体清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体;
1.4将复合粉体放入高温烧结反应炉中,通入体积百分比比例为1:15的氢氩混合气体,加热到600℃,反应13h得到氢镁素。
S2、将氢镁素和苹果酸按比例混合均匀,得到混合芯材;
S3:按比例称取海藻酸钠、乙基纤维素和透明质酸钠加入水中,加热溶解,搅拌均匀得到壁材溶液;
S3:将混合芯材加入壁材溶液中,充分混合后高压均质,采用喷雾干燥法制备得到氢镁素微胶囊,喷雾干燥法的具体参数为:进风温度为180℃,进样速度为2ml〃min-1,吸气功率为90%。
实施例2
一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素微胶囊 160份
γ-氨基丁酸 180份
烟酰胺 2份
氢镁素微胶囊中混合芯材与复合壁材的质量百分比比例为1:2;混合芯材为质量百分比比例为4:15的氢镁素和苹果酸;复合壁材为质量百分比比例为8:3:2的海藻酸钠、乙基纤维素和透明质酸钠;
氢镁素微胶囊通过喷雾干燥法制备得到,具体方法包括以下步骤:
S1、氢镁素的制备
1.1以氧化镁为原料,在2500℃下加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体;
1.2制备改性介孔二氧化硅:将六水合碳酸铈加入浓度为0.012g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为0.1:1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅;
1.3将氧化镁晶体与改性介孔二氧化硅加入N,N-二甲基甲酰胺中搅拌均匀后离心,将离心后的固体清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体;
1.4将复合粉体放入高温烧结反应炉中,通入体积百分比比例为1:15的氢氩混合气体,加热到600℃,反应13h得到氢镁素。
S2、将氢镁素和苹果酸按比例混合均匀,得到混合芯材;
S3:按比例称取海藻酸钠、乙基纤维素和透明质酸钠加入水中,加热溶解,搅拌均匀得到壁材溶液;
S3:将混合芯材加入壁材溶液中,充分混合后高压均质,采用喷雾干燥法制备得到氢镁素微胶囊,喷雾干燥法的具体参数为:进风温度为180℃,进样速度为2ml〃min-1,吸气功率为90%。
实施例3
30名成年健康人为对象,实施跟踪调查。每天喝2包(早〃晚)含该组合物的固体饮料(10克/包),第15天和第30天测试美容效果。
结果:30天后,大约60%的人感觉到皮肤紧致,保湿效果明显,粉刺红肿等皮肤炎症明显改善。持续使用后,效果增加。可改善皮肤保湿和经表皮水分流失,减少黑斑色素沉着。
实施例4
同一地区的30名受试者使用含该组合物的护肤品28天检测结果如下∶
皮肤亮白度L值:连续使用测试组合28天,受试者的皮肤亮白度L值在产品使用14天与基础值相比有显著性上升(p<0.001),上升率为0.99%;在产品使用28天与基础值相比有显著性上升(p<0.001),上升率为2.04%。
皮肤明亮度ITA°值:连续使用测试组合28天,受试者的皮肤明亮度ITA°值产品在产品使用14天与基础值相比有显著上升(p<0.001),上升率为3.14%;在产品使用28天与基础值相比有显著性上升(p<0.001),上升率为7.89%。
皮肤黑色素含量:连续使用组合28天,受试者的皮肤黑色素含量在产品使用14天与基础值相比有显著性下降(p<0.001),下降率为4.89%;在产品使用28天与基础值相比有显著下降(p<0.001),下降率为11.7%。
Visia-CR色斑面积占比
连续使用测试组合28天,受试者的Visia-CR色斑面积占在产品使用14天与基础值相比有显著性下降p<0.001),下降率为4.36%∶在产品使用28天与基础值相比有显著性下降(p<0.001),下降率为7.95%。
Visia-CR肤色均匀度(HSV)
连续使用测试组合28天,受试者的Visia-CR肤色均匀度(HSV)在产品使用14天与基础值相比有显著性下降(0.001<p<0.01),下降率为2.85%;在产品使用28天与基础值相比有显著性下降(p<0.001),下降率为5.72%。
Visia-CR毛孔面积占比
连续使用测组合28天,受试者的Visia-CR毛孔面积占比在产品使用14天与基础值相比无显著性变化(p>0.05),下降率为1.27%;在产品使用28天与基础值相比无显著性变化(p>0.05),下降率为4.63%。
结果:该组合物在因日晒、污染引起的氧化应激引起的皮肤损伤,具有美白、提亮肤色、淡化皮肤黑色素、减少色斑的功效,改善皮肤保湿和经表皮水分流失,减少黑斑色素沉着。
对比例1
对比例1与实施例1的区别在于组合物中氢镁素微胶囊的添加量较少,且氢镁素微胶囊的混合芯材中氢镁素的占比较少,具体如下所示:
一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素微胶囊 50份
γ-氨基丁酸 280份
烟酰胺 3份
氢镁素微胶囊中混合芯材与复合壁材的质量百分比比例为1:3;混合芯材为质量百分比比例为1:20的氢镁素和苹果酸;复合壁材为质量百分比比例为8:3:2的海藻酸钠、乙基纤维素和透明质酸钠。
对比例2
对比例2与实施例1的区别在于本对比例使用氢镁素粉末,具体如下:
一种包含氢镁素的缓释抗氧化组合物,以重量份计,包括以下组分:
氢镁素 150份
γ-氨基丁酸 180份
烟酰胺 3份
S1、氢镁素的制备
1.1以氧化镁为原料,在2500℃下加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体;
1.2制备改性介孔二氧化硅:将六水合碳酸铈加入浓度为0.012g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为0.1:1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅;
1.3将氧化镁晶体与改性介孔二氧化硅加入N,N-二甲基甲酰胺中搅拌均匀后离心,将离心后的固体清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体;
1.4将复合粉体放入高温烧结反应炉中,通入体积百分比比例为1:15的氢氩混合气体,加热到600℃,反应13h得到氢镁素。
以上介绍了本发明的较佳实施方式,旨在使得本发明的精神更加清楚和便于理解,并不是为了限制本发明,凡在本发明的精神和原则之内,所做的修改、替换、改进,均应包含在本发明所附的权利要求概括的保护范围之内。
Claims (8)
1.一种包含氢镁素的缓释抗氧化组合物,其特征在于,以重量份计,包括以下组分:
氢镁素微胶囊 80-160份
γ-氨基丁酸 180-220份
烟酰胺 1-4份
所述氢镁素微胶囊为,以氢镁素和苹果酸为混合芯材,海藻酸钠、乙基纤维素和透明质酸钠为复合壁材,通过喷雾干燥法制备得到;
所述芯材与壁材的质量比为1:(2-3.5);
所述混合芯材中氢镁素和苹果酸的质量比为(3-5):(10-20);
所述氢镁素以氧化镁为原料,在高温下通过与氢氩混合气体的氢化反应制备得到,所述氢镁素的制备方法为:超高温加热得到熔融态氧化镁,通过定向凝固得到氧化镁晶体;将氧化镁晶体与改性介孔二氧化硅加入有机溶液中搅拌均匀后离心,将离心后的固体用有机溶剂清洗干燥,加入聚乙二醇,搅拌研磨得到复合粉体;将复合粉体放入高温烧结反应炉中,通入氢氩混合气体,加热到400-800℃,反应12-15h得到氢镁素;
所述改性介孔二氧化硅为经过铈改性的纳米介孔二氧化硅,制备方法为:将六水合碳酸铈加入浓度为0.010-0.013g/ml的介孔二氧化硅水溶液中,搅拌至完全溶解,铈和硅的摩尔比为(0.07-0.10):1;加入碳酸氢钠溶液,在室温下持续搅拌8-12h,抽滤洗涤,在80-100℃下干燥,静置10-12h,制备得到改性介孔二氧化硅。
2.如权利要求1所述的组合物,其特征在于,所述组合物还包括益生菌。
3.如权利要求1所述的组合物,其特征在于,所述氢镁素微胶囊的制备方法包括以下步骤:
S1:将氢镁素和苹果酸混合均匀,得到混合芯材;
S2:称取海藻酸钠、乙基纤维素和透明质酸钠加入水中,加热溶解,搅拌均匀得到壁材溶液;
S3:将混合芯材加入壁材溶液中,充分混合后高压均质,采用喷雾干燥法制备得到氢镁素微胶囊。
4.如权利要求3所述的组合物,其特征在于,所述喷雾干燥法的具体参数为:进风温度为120-200℃,进样速度为1.5-4 ml/min,吸气功率为80-100%。
5.如权利要求3或4所述的组合物,其特征在于,所述壁材中海藻酸钠、乙基纤维素和透明质酸钠的质量比为(7-10):(2-3):(1-2)。
6.如权利要求1所述的组合物,其特征在于,所述超高温加热的温度为2500-3000℃。
7.如权利要求6所述的组合物,其特征在于,所述氢氩混合气体中氢气与氩气的体积比为1:(14-16)。
8.一种如权利要求1-7任一项所述的组合物在抗衰老药品、或抗衰老护肤品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211104598.XA CN115428945B (zh) | 2022-09-09 | 2022-09-09 | 一种包含氢镁素的缓释抗氧化组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211104598.XA CN115428945B (zh) | 2022-09-09 | 2022-09-09 | 一种包含氢镁素的缓释抗氧化组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115428945A CN115428945A (zh) | 2022-12-06 |
CN115428945B true CN115428945B (zh) | 2024-02-27 |
Family
ID=84246969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211104598.XA Active CN115428945B (zh) | 2022-09-09 | 2022-09-09 | 一种包含氢镁素的缓释抗氧化组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115428945B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102783691A (zh) * | 2012-08-20 | 2012-11-21 | 李志林 | 一种钙镁制氢剂 |
CN104306398A (zh) * | 2014-09-18 | 2015-01-28 | 宋忠慎 | 负氢离子抗氧化剂和锌、硼元素补充剂的低成本制备方法 |
CN109224029A (zh) * | 2018-09-30 | 2019-01-18 | 泓博元生命科技(深圳)有限公司 | 含有nmn的降血脂组合物、制剂及其制备方法与应用 |
CN114848513A (zh) * | 2022-06-07 | 2022-08-05 | 河北云悦生物科技有限公司 | 一种复合富氢材料及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3310392A4 (en) * | 2015-06-19 | 2019-03-27 | Global Health Solutions, LLC | VASELINE ADMINISTRATION SYSTEMS FOR ACTIVE INGREDIENTS |
-
2022
- 2022-09-09 CN CN202211104598.XA patent/CN115428945B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102783691A (zh) * | 2012-08-20 | 2012-11-21 | 李志林 | 一种钙镁制氢剂 |
CN104306398A (zh) * | 2014-09-18 | 2015-01-28 | 宋忠慎 | 负氢离子抗氧化剂和锌、硼元素补充剂的低成本制备方法 |
CN109224029A (zh) * | 2018-09-30 | 2019-01-18 | 泓博元生命科技(深圳)有限公司 | 含有nmn的降血脂组合物、制剂及其制备方法与应用 |
CN114848513A (zh) * | 2022-06-07 | 2022-08-05 | 河北云悦生物科技有限公司 | 一种复合富氢材料及其制备方法 |
Non-Patent Citations (1)
Title |
---|
孙酣经等.《化工新材料产品及应用手册》.中国石化出版社,2002,(第1版),第1218页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115428945A (zh) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2543370A1 (en) | Formulations for topical delivery of bioactive substances and methods for their use | |
US20210259991A1 (en) | Methods and Compositions for Delivering Retinaldehyde to a Topical Location of a Subject | |
US20200000704A1 (en) | Degradation inhibitor of hyaluronic acid, comprising rosemary extract and retinol acetate | |
CN115428945B (zh) | 一种包含氢镁素的缓释抗氧化组合物及其应用 | |
CN109125099B (zh) | 一种可持续释放氢气的面膜及其使用方法 | |
CN116807952A (zh) | 一种植物提取活性组合物及其制备方法 | |
CN112168750A (zh) | 一种人参皂苷提取物的制备方法及其在护肤品中的应用 | |
CN113952250B (zh) | 一种稳定的抗光老化组合物及其制备方法 | |
JP2002275018A (ja) | 皮膚外用剤 | |
CN112545970B (zh) | 一种美容护肤珍珠膏及其制备方法 | |
US10449129B2 (en) | Encapsulates of salicylic acid and polysalicylic acid derivatives | |
CN113693966B (zh) | 一种美白淡斑亮采霜及其制备方法 | |
CN108294960A (zh) | 一种富氢美容面膜及其制备方法 | |
CN111483977B (zh) | 一种溶于水可瞬间产生高浓度氢的复合物及其制备方法 | |
CN114403333A (zh) | 一种防中暑抗疲劳的泡腾片及其制备方法 | |
CN114588074B (zh) | 一种抗衰老美白保湿面膜及其制备方法 | |
CN111870546A (zh) | 富氢面膜及其制备方法 | |
Nurfitriyawatie et al. | Antiphotoaging effects of liposomal encapsulated superoxide dismutase extract of Bacillus altitudinis on ultraviolet-A-irradiated New Zealand rabbits’ back skin | |
CN114931516B (zh) | 一种含有一氧化氮脂质体的乳液及其制备方法 | |
JP2008074844A (ja) | ビタミンc効能増強組成物 | |
KR20190112879A (ko) | 유자 씨앗 배아 발효 성분에 기초하는 천연미백제의 제조방법 | |
KR100447533B1 (ko) | 피부미백 및 주름개선용 피부 외용제 조성물 | |
JP2009298728A (ja) | 細胞賦活剤、及び老化防止用皮膚外用剤 | |
CN107440969B (zh) | 一种防晒修复剂及其应用 | |
KR101152326B1 (ko) | 피부미백 및 주름개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230817 Address after: Room 519, Building 6, No.1 Xuefu Road, Songshan Lake Park, Dongguan City, Guangdong Province, 523830 Applicant after: Guangdong Hydrogen Beauty Yanmeng Intelligent Health Technology Co.,Ltd. Address before: 200240 Block C, room 01, 3rd floor, Ding building, 555 Dongchuan Road, Minhang District, Shanghai Applicant before: Shanghai hydrogen Health Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |